Guardant Health, Inc.(GH)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
GH | 21.61 B | -46.68x | 44.30% | -38.33% | $-3.45 | - | - | - | $176.58 | $53.40 |
CVS | 124.32 B | 25.65x | 7.10% | 1.18% | $3.79 | 6.21% | 0.95 | 2.86% | $110.00 | $67.46 |
CI | 75.64 B | 11.96x | 6.70% | 2.27% | $23.94 | 16.76% | 0.74 | 2.24% | $310.19 | $235.50 |
LH | 26.88 B | 27.60x | 5.80% | 6.99% | $12.01 | 11.73% | 0.79 | 86.00% | $341.07 | $242.07 |
DGX | 26.42 B | 25.69x | 10.20% | 9.19% | $9.32 | 14.60% | 0.81 | 1.42% | $247.19 | $168.97 |
Peer Valuation & Performance Analysis
Peer group analysis for Guardant Health, Inc. (GH) compared to its primary competitors (including CVS, CI, LH) reveals distinct metrics. GH trades at a valuation discount relative to its competitors, with a P/E ratio of -46.7x versus the peer average of 22.7x (representing a 305% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, GH's revenue growth of 44.3% exceeds the peer average of 7.5%, highlighting its competitive strength and market share gains. Additionally, its net margin of -38.3% is below the peer average of 4.9%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• GH ranks #0 in P/E ratio, #1 in revenue growth, and #5 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $164.09 | $166.42 | $159.59 | $161.04 | 1,190,800 | -1.86% |
| 2026-09-02 | $163.79 | $168.97 | $157.35 | $163.06 | 1,757,200 | -0.45% |
| 2026-09-01 | $158.50 | $165.63 | $156.32 | $164.41 | 2,437,400 | +3.73% |
| 2026-08-31 | $160.01 | $162.14 | $155.63 | $159.02 | 1,857,100 | -0.62% |
| 2026-08-28 | $166.35 | $169.60 | $160.23 | $161.50 | 1,820,800 | -2.92% |
| 2026-08-27 | $170.94 | $173.10 | $168.19 | $168.52 | 1,517,500 | -1.42% |
| 2026-08-26 | $164.71 | $173.17 | $164.29 | $170.92 | 2,010,600 | +3.77% |
| 2026-08-25 | $164.54 | $167.90 | $161.22 | $164.92 | 1,188,300 | +0.23% |
| 2026-08-24 | $164.62 | $167.48 | $162.00 | $163.18 | 2,211,300 | -0.87% |
| 2026-08-21 | $167.25 | $170.85 | $165.01 | $170.69 | 1,914,100 | +2.06% |
| 2026-08-20 | $161.55 | $171.74 | $161.55 | $167.88 | 2,549,000 | +3.92% |
| 2026-08-19 | $165.51 | $168.73 | $159.46 | $163.34 | 2,384,800 | -1.31% |
| 2026-08-18 | $160.72 | $164.26 | $158.81 | $160.12 | 1,202,100 | -0.37% |
| 2026-08-17 | $156.45 | $162.96 | $155.00 | $161.67 | 4,858,400 | +3.34% |
| 2026-08-14 | $157.93 | $159.71 | $156.21 | $157.21 | 2,564,800 | -0.46% |
Explore More Analysis for GH
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.